PMID- 36230603
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221017
IS  - 2072-6694 (Print)
IS  - 2072-6694 (Electronic)
IS  - 2072-6694 (Linking)
VI  - 14
IP  - 19
DP  - 2022 Sep 26
TI  - Plant-Derived Sulforaphane Suppresses Growth and Proliferation of Drug-Sensitive 
      and Drug-Resistant Bladder Cancer Cell Lines In Vitro.
LID - 10.3390/cancers14194682 [doi]
LID - 4682
AB  - Combined cisplatin-gemcitabine (GC) application is standard for treating 
      muscle-invasive bladder cancer. However, since rapid resistance to treatment 
      often develops, many patients turn to supplements in the form of plant-based 
      compounds. Sulforaphane (SFN), derived from cruciferous vegetables, is one such 
      compound, and the present study was designed to investigate its influence on 
      growth and proliferation in a panel of drug-sensitive bladder cancer cell lines, 
      as well as their gemcitabine- and cisplatin-resistant counterparts. 
      Chemo-sensitive and -resistant RT4, RT112, T24, and TCCSUP cell lines were 
      exposed to SFN in different concentrations, and tumor growth, proliferation, and 
      clone formation were evaluated, in addition to apoptosis and cell cycle 
      progression. Means of action were investigated by assaying cell-cycle-regulating 
      proteins and the mechanistic target of rapamycin (mTOR)/AKT signaling cascade. 
      SFN significantly inhibited growth, proliferation, and clone formation in all 
      four tumor cell lines. Cells were arrested in the G2/M and/or S phase, and 
      alteration of the CDK-cyclin axis was closely associated with cell growth 
      inhibition. The AKT/mTOR signaling pathway was deactivated in three of the cell 
      lines. Acetylation of histone H3 was up-regulated. SFN, therefore, does exert 
      tumor-suppressive properties in cisplatin- and gemcitabine-resistant bladder 
      cancer cells and could be beneficial in optimizing bladder cancer therapy.
FAU - Xie, Hui
AU  - Xie H
AUID- ORCID: 0000-0002-6219-1696
AD  - Department of Urology and Pediatric Urology, University Medical Center Mainz, 
      55131 Mainz, Germany.
AD  - Department of Urology, Goethe-University, 60590 Frankfurt am Main, Germany.
FAU - Rutz, Jochen
AU  - Rutz J
AD  - Department of Urology and Pediatric Urology, University Medical Center Mainz, 
      55131 Mainz, Germany.
FAU - Maxeiner, Sebastian
AU  - Maxeiner S
AD  - Department of Urology and Pediatric Urology, University Medical Center Mainz, 
      55131 Mainz, Germany.
FAU - Grein, Timothy
AU  - Grein T
AD  - Department of Urology and Pediatric Urology, University Medical Center Mainz, 
      55131 Mainz, Germany.
FAU - Thomas, Anita
AU  - Thomas A
AD  - Department of Urology and Pediatric Urology, University Medical Center Mainz, 
      55131 Mainz, Germany.
FAU - Juengel, Eva
AU  - Juengel E
AUID- ORCID: 0000-0002-6321-8707
AD  - Department of Urology and Pediatric Urology, University Medical Center Mainz, 
      55131 Mainz, Germany.
FAU - Chun, Felix K-H
AU  - Chun FK
AD  - Department of Urology, Goethe-University, 60590 Frankfurt am Main, Germany.
FAU - Cinatl, Jindrich
AU  - Cinatl J
AD  - Institute of Medical Virology, University Hospital, Goethe-University, 60596 
      Frankfurt am Main, Germany.
FAU - Haferkamp, Axel
AU  - Haferkamp A
AD  - Department of Urology and Pediatric Urology, University Medical Center Mainz, 
      55131 Mainz, Germany.
FAU - Tsaur, Igor
AU  - Tsaur I
AUID- ORCID: 0000-0001-5107-3523
AD  - Department of Urology and Pediatric Urology, University Medical Center Mainz, 
      55131 Mainz, Germany.
FAU - Blaheta, Roman A
AU  - Blaheta RA
AUID- ORCID: 0000-0002-0129-7972
AD  - Department of Urology and Pediatric Urology, University Medical Center Mainz, 
      55131 Mainz, Germany.
LA  - eng
GR  - 201707660003/the Brigitta & Norbert Muth Stiftung, Wiesbaden, Germany, the 
      Eden-Stiftung, Bad Soden, Germany, the Brigitte und Dr. Konstanze 
      Wegener-Stiftung, Dusseldorf, Germany, and the China Scholarship Council/
PT  - Journal Article
DEP - 20220926
PL  - Switzerland
TA  - Cancers (Basel)
JT  - Cancers
JID - 101526829
PMC - PMC9564120
OTO - NOTNLM
OT  - AKT/mTOR
OT  - bladder cancer
OT  - drug resistance
OT  - proliferation
OT  - sulforaphane
COIS- The authors declare no conflict of interest.
EDAT- 2022/10/15 06:00
MHDA- 2022/10/15 06:01
PMCR- 2022/09/26
CRDT- 2022/10/14 01:51
PHST- 2022/08/25 00:00 [received]
PHST- 2022/09/20 00:00 [revised]
PHST- 2022/09/21 00:00 [accepted]
PHST- 2022/10/14 01:51 [entrez]
PHST- 2022/10/15 06:00 [pubmed]
PHST- 2022/10/15 06:01 [medline]
PHST- 2022/09/26 00:00 [pmc-release]
AID - cancers14194682 [pii]
AID - cancers-14-04682 [pii]
AID - 10.3390/cancers14194682 [doi]
PST - epublish
SO  - Cancers (Basel). 2022 Sep 26;14(19):4682. doi: 10.3390/cancers14194682.